Targeted protein degradation in hematologic malignancies: latest updates from the 2023 ASH annual meeting

Abstract

Abstract Protein degraders, emerging as a novel class of therapeutic agents, have gained widespread attention due to their advantages. They have several advantages over traditional small molecule inhibitors, including high target selectivity and ability to target “undruggable” targets and overcome inhibitor drug resistance. Tremendous research and development efforts and massive investment have resulted in rapid advancement of protein degrader drug discovery in recent years. Here, we overview the latest clinical and preclinical updates on protein degraders presented at the 2023 ASH Annual Meeting.

Keywords

• Protein degradation
• Anti-tumor therapy
• Hematologic malignancies